Positive News Sentiment NASDAQ:SIBN SI-BONE Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding SI-BONE, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $13.52 -0.03 (-0.22%) (As of 07/6/2022 12:00 AM ET) Add Compare Share Today's Range$13.23▼$13.9650-Day Range$12.05▼$20.5152-Week Range$11.89▼$31.54Volume85,517 shsAverage Volume167,170 shsMarket Capitalization$458.06 millionP/E RatioN/ADividend YieldN/APrice Target$31.57 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability SI-BONE MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside133.5% Upside$31.57 Price TargetShort InterestBearish6.41% of Float Sold ShortDividend StrengthN/ASustainability-1.44Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$369,455 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.93) to ($1.72) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.2.21 out of 5 starsMedical Sector269th out of 1,433 stocksSurgical & Medical Instruments Industry35th out of 137 stocks 3.5 Analyst's Opinion Consensus RatingSI-BONE has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $31.57, SI-BONE has a forecasted upside of 133.5% from its current price of $13.52.Amount of Analyst CoverageSI-BONE has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.41% of the float of SI-BONE has been sold short.Short Interest Ratio / Days to CoverSI-BONE has a short interest ratio ("days to cover") of 5.9.Change versus previous monthShort interest in SI-BONE has recently increased by 17.22%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSI-BONE does not currently pay a dividend.Dividend GrowthSI-BONE does not have a long track record of dividend growth. Previous Next 2.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSI-BONE has received a 34.81% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Cervical implants" product. See details.Environmental SustainabilityThe Environmental Impact score for SI-BONE is -1.44. Previous Next 2.7 News and Social Media Coverage News SentimentSI-BONE has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, SI-BONE insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $369,455.00 in company stock.Percentage Held by InsidersOnly 5.40% of the stock of SI-BONE is held by insiders.Percentage Held by Institutions99.36% of the stock of SI-BONE is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for SI-BONE are expected to grow in the coming year, from ($1.93) to ($1.72) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of SI-BONE is -7.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of SI-BONE is -7.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSI-BONE has a P/B Ratio of 3.37. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive SIBN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SI-BONE and its competitors with MarketBeat's FREE daily newsletter. Email Address About SI-BONE (NASDAQ:SIBN) StockSI-BONE, Inc., a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers iFuse, a minimally invasive surgical implant system to address sacroiliac joint dysfunction and degeneration, adult deformity, and pelvic ring traumatic fractures. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; and iFuse-TORQ, a set of 3D-printed threaded implants designed to treat fractures of the pelvis and for minimally invasive sacroiliac joint fusion. It markets its products primarily with a direct sales force, as well as through distributors. The company was incorporated in 2008 and is headquartered in Santa Clara, California.Read More SIBN Stock News HeadlinesJune 23, 2022 | americanbankingnews.comSI-BONE, Inc. (NASDAQ:SIBN) Receives $31.57 Average PT from BrokeragesJune 15, 2022 | americanbankingnews.comSI-BONE, Inc. (NASDAQ:SIBN) Director Jeryl L. Hilleman Sells 1,924 SharesJune 13, 2022 | nz.finance.yahoo.comSI-BONE, Inc. Announces FDA Clearance for Expanded Indication of the iFuse-TORQ® Implant SystemJune 2, 2022 | seekingalpha.comAurora Spine Has Three Shots On GoalMay 31, 2022 | seekingalpha.comSI-BONE iFuse Bedrock Granite for pelvic fixation gets FDA nodMay 31, 2022 | finance.yahoo.comSI-BONE, Inc. Receives FDA 510(k) Clearance for iFuse Bedrock Granite, a Breakthrough Pelvic Fixation and Fusion TechnologyMay 9, 2022 | seekingalpha.comSI-BONE, Inc.'s (SIBN) CEO Laura Francis on Q1 2022 Results - Earnings Call TranscriptMay 9, 2022 | finance.yahoo.comSI-BONE, Inc. Reports First Quarter 2022 Financial ResultsMay 7, 2022 | theglobeandmail.comInstrument Name Si-Bone Inc Instrument Symbol (SIBN-Q)May 3, 2022 | nasdaq.comNotable Tuesday Option Activity: SIBN, IPI, SITMMay 2, 2022 | finance.yahoo.comEarnings Preview: Si-Bone (SIBN) Q1 Earnings Expected to DeclineApril 19, 2022 | finance.yahoo.comSI-BONE, Inc. Announces New Technology Add-On Payment for Breakthrough Adult Spinal Deformity TreatmentApril 18, 2022 | finance.yahoo.comSI-BONE To Present at BofA Securities 2022 Healthcare ConferenceApril 18, 2022 | finance.yahoo.comSI-BONE To Report First Quarter 2022 Financial Results on May 9, 2022February 28, 2022 | benzinga.comSI-BONE: Q4 Earnings InsightsFebruary 28, 2022 | finance.yahoo.comSI-BONE, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Issues 2022 Revenue GuidanceFebruary 28, 2022 | finance.yahoo.comSI-BONE, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Issues 2022 Revenue GuidanceFebruary 11, 2022 | nasdaq.comSelling US$1.7m worth of SI-BONE, Inc. (NASDAQ:SIBN) stock at high prices would have gotten insiders a handsome rewardFebruary 1, 2022 | finance.yahoo.comSI-BONE To Report Fourth Quarter and Full Year 2021 Financial Results on February 28, 2022January 10, 2022 | seekingalpha.comSI-BONE guides Q4 and FY21 revenue above consensusJanuary 10, 2022 | finance.yahoo.comSI-BONE Announces Revenue for the Fourth Quarter and Full Year 2021January 3, 2022 | finance.yahoo.comShareholders in SI-BONE (NASDAQ:SIBN) are in the red if they invested a year agoDecember 27, 2021 | finance.yahoo.comSI-BONE to participate in 24th Annual Needham Virtual Growth ConferenceDecember 13, 2021 | finance.yahoo.comSI-BONE, Inc. Announces Updated Exclusive Blue Cross Blue Shield Association Evidence Street Opinion, and New Coverage Policies from Arkansas Blue Cross Blue Shield and Walmart Plans from BlueAdvantage Administrators of ArkansasDecember 12, 2021 | finance.yahoo.comIs SI-BONE, Inc. (SIBN) Going to Burn These Hedge Funds?See More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SIBN CUSIPN/A CIK1459839 Webwww.si-bone.com Phone(408) 207-0700FaxN/AEmployees352Year FoundedN/ACompany Calendar Last Earnings5/09/2022Today7/07/2022Next Earnings (Estimated)8/01/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$31.57 High Stock Price Forecast$36.00 Low Stock Price Forecast$25.00 Forecasted Upside/Downside+133.5%Consensus RatingBuy Rating Score (0-4)3 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.85) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-56,570,000.00 Net Margins-67.00% Pretax Margin-67.00% Return on Equity-44.52% Return on Assets-32.13% Debt Debt-to-Equity Ratio0.29 Current Ratio10.44 Quick Ratio9.48 Sales & Book Value Annual Sales$90.15 million Price / Sales5.08 Cash FlowN/A Price / Cash FlowN/A Book Value$4.01 per share Price / Book3.37Miscellaneous Outstanding Shares33,880,000Free Float32,054,000Market Cap$458.06 million OptionableNot Optionable Beta1.41 SI-BONE Frequently Asked Questions Should I buy or sell SI-BONE stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for SI-BONE in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SI-BONE stock. View analyst ratings for SI-BONE or view top-rated stocks. What is SI-BONE's stock price forecast for 2022? 6 brokerages have issued 1 year price objectives for SI-BONE's shares. Their SIBN stock forecasts range from $25.00 to $36.00. On average, they predict SI-BONE's share price to reach $31.57 in the next twelve months. This suggests a possible upside of 133.5% from the stock's current price. View analysts' price targets for SI-BONE or view top-rated stocks among Wall Street analysts. How has SI-BONE's stock performed in 2022? SI-BONE's stock was trading at $22.21 at the beginning of 2022. Since then, SIBN stock has decreased by 39.1% and is now trading at $13.52. View the best growth stocks for 2022 here. When is SI-BONE's next earnings date? SI-BONE is scheduled to release its next quarterly earnings announcement on Monday, August 1st 2022. View our earnings forecast for SI-BONE. How were SI-BONE's earnings last quarter? SI-BONE, Inc. (NASDAQ:SIBN) announced its earnings results on Monday, May, 9th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.43) by $0.09. The business had revenue of $22.44 million for the quarter, compared to analysts' expectations of $22.37 million. SI-BONE had a negative trailing twelve-month return on equity of 44.52% and a negative net margin of 67.00%. During the same period last year, the firm posted ($0.37) earnings per share. View SI-BONE's earnings history. What guidance has SI-BONE issued on next quarter's earnings? SI-BONE updated its FY 2022 earnings guidance on Monday, June, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $106.00 million-$108.00 million, compared to the consensus revenue estimate of $107.35 million. Who are SI-BONE's key executives? SI-BONE's management team includes the following people: Ms. Laura A. Francis MBA, CEO & Director (Age 55, Pay $879.74k) (LinkedIn Profile)Mr. Anshul Maheshwari, Chief Financial Officer (Age 44, Pay $511.05k)Mr. Anthony J. Recupero, Pres of Commercial Operations (Age 63, Pay $665.91k) (LinkedIn Profile)Mr. Michael A. Pisetsky, Sr. VP of Operations & Admin., Sec. and Chief Legal Officer (Age 44) (LinkedIn Profile)Dr. Scott A. Yerby, Sr. VP of Engineering & CTO (Age 54)Mr. Joseph W. Powers, VP of Corp. Marketing (Age 62)Dr. Daniel Joseph Cher, Sr. VP of Clinical & Regulatory Affairs (Age 57)Dr. W. Carlton Reckling, Chief Medical Officer & VP of Medical Affairs (Age 60)Mr. Nikolas F. Kerr, Sr. VP of Product, Strategy & Bus. Devel. (Age 50)Ms. Joyce Goto, VP & Corp. Controller (Age 48) What is Jeffrey Dunn's approval rating as SI-BONE's CEO? 10 employees have rated SI-BONE CEO Jeffrey Dunn on Glassdoor.com. Jeffrey Dunn has an approval rating of 41% among SI-BONE's employees. This puts Jeffrey Dunn in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. Who are some of SI-BONE's key competitors? Some companies that are related to SI-BONE include Nevro (NVRO), Embecta (EMBC), PROCEPT BioRobotics (PRCT), Paragon 28 (FNA), Silk Road Medical (SILK), Atrion (ATRI), LeMaitre Vascular (LMAT), Cerus (CERS), Antares Pharma (ATRS), Intersect ENT (XENT), OrthoPediatrics (KIDS), Treace Medical Concepts (TMCI), Longview Acquisition Corp. II (LGV), Artivion (AORT) and AngioDynamics (ANGO). View all of SIBN's competitors. What other stocks do shareholders of SI-BONE own? Based on aggregate information from My MarketBeat watchlists, some companies that other SI-BONE investors own include (HON), CVS Health (CVS), Home Depot (HD), Procter & Gamble (PG), Raytheon Technologies (RTX), Thermo Fisher Scientific (TMO), Verizon Communications (VZ), Alibaba Group (BABA), Cisco Systems (CSCO) and CSX (CSX). When did SI-BONE IPO? (SIBN) raised $84 million in an initial public offering on Wednesday, October 17th 2018. The company issued 6,000,000 shares at a price of $13.00-$15.00 per share. Morgan Stanley and BofA Merrill Lynch served as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers. What is SI-BONE's stock symbol? SI-BONE trades on the NASDAQ under the ticker symbol "SIBN." How do I buy shares of SI-BONE? Shares of SIBN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is SI-BONE's stock price today? One share of SIBN stock can currently be purchased for approximately $13.52. How much money does SI-BONE make? SI-BONE (NASDAQ:SIBN) has a market capitalization of $458.06 million and generates $90.15 million in revenue each year. The company earns $-56,570,000.00 in net income (profit) each year or ($1.85) on an earnings per share basis. How many employees does SI-BONE have? SI-BONE employs 352 workers across the globe. How can I contact SI-BONE? SI-BONE's mailing address is 471 EL CAMINO REAL SUITE 101, SANTA CLARA CA, 95050. The official website for SI-BONE is www.si-bone.com. The company can be reached via phone at (408) 207-0700 or via email at investors@si-bone.com. This page (NASDAQ:SIBN) was last updated on 7/7/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
